Native GHRH(1-29)/sermorelin has genuine human endocrine and diagnostic evidence. In a tiny 6-week study of older men, nightly GHRH increased nocturnal GH but did not significantly improve IGF-I or DEXA body composition.
Regulatory status
Historical FDA marketing approval existed for Geref (sermorelin acetate); this does not confer approval on generic research-market sermorelin.
Main limitations
General anti-ageing, fat-loss, muscle-building or longevity efficacy in otherwise healthy adults.
Safety
GH-axis adverse effects and contraindications are context-specific; unregulated products add purity/identity uncertainty.
i
Native GHRH(1-29)/sermorelin has genuine human endocrine and diagnostic evidence. In a tiny 6-week study of older men, nightly GHRH increased nocturnal GH but did not significantly improve IGF-I or DEXA body composition.
What the evidence actually supports
✓Strong human endocrine evidence, but outcome claims must stay indication-specific.
✓Useful evidence against oversimplifying 'raises GH' into 'rejuvenates or burns fat'.
What is not established / key limitations
×Target engagement does not establish lifestyle benefits.
×No DEXA body-composition improvement in this small study.
Selected study & evidence records
Comparison of GHRH(1-40) and GHRH(1-29)NH2 in young adults and children
1986 · Human diagnostic/physiology study · n=142
GHRH(1-29)NH2 produced GH responses useful for testing pituitary GH reserve; responses varied by underlying diagnosis.
1997 · Randomized placebo-controlled clinical physiology study · n=11
Nocturnal GH increased, but IGF-I did not significantly increase; 2 of 6 strength/performance measures improved while DEXA body composition did not change.
GH-axis adverse effects and contraindications are context-specific; unregulated products add purity/identity uncertainty.
Historical clinical use provides more human exposure than most research peptides, but modern anti-ageing/body-composition use is not the same indication.
Technical details
Mechanism / biologyStimulates pituitary GHRH receptors to release endogenous GH.
Route / formulation boundaryCurrent authorization and product quality must be checked by jurisdiction/product.
Identity / data-quality noteUse the canonical compound identity and studied formulation when interpreting evidence.
Dosing evidence statusHuman pharmacology dosing verified. A small endocrine study tested IV GHRH(1-29)-NH2/sermorelin at 0.1 and 1.0 micrograms/kg as pulsed challenge doses. This is pharmacology evidence, not a routine self-use regimen.
Evidence rule: WhichPeps keeps human, animal, laboratory, regulatory and product/formulation evidence distinct. Common names help people find the page; they do not change the underlying scientific identity.
